Thermon Group Holdings, Inc. (THR)


NYSE - NYSE Real Time Price. Currency in USD
19.80+0.11 (+0.56%)
At close: 4:02 PM EDT
People also watch:
TOWRTRNOTREXTNCTRS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open19.55
Prev Close19.69
Bid19.78 x 400
Ask19.79 x 100
Day's Range19.58 - 20.00
52wk Range13.97 - 22.96
1y Target EstN/A
Market Cap638.71M
P/E Ratio (ttm)30.46
Beta1.04
Volume70,741
Avg Vol (3m)110,728
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube15 days ago

    ETF’s with exposure to Thermon Group Holdings, Inc. : August 11, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Thermon Group Holdings, Inc. Here are 5 ETF’s with the largest exposure to THR-US. Comparing the performance and risk of Thermon Group Holdings, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Thermon Group Holdings, Inc. :THR-US: Earnings Analysis: Q1, 2017 By the Numbers : August 10, 2016
    Capital Cube16 days ago

    Thermon Group Holdings, Inc. :THR-US: Earnings Analysis: Q1, 2017 By the Numbers : August 10, 2016

    Categories: Yahoo Finance Click here to see latest analysis Thermon Group Holdings, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Thermon Group Holdings, Inc. – 3M Company, Dow Chemical Company, Fluor Corporation and E. I. du Pont de Nemours and Company (MMM-US, DOW-US, FLR-US and ... Read more (Read more...)

  • ThromboGenics NV :THR-BE: Earnings Analysis: For the six months ended December 31, 2015 : August 4, 2016
    Capital Cube22 days ago

    ThromboGenics NV :THR-BE: Earnings Analysis: For the six months ended December 31, 2015 : August 4, 2016

    Categories: Yahoo Finance Click here to see latest analysis ThromboGenics NV reports financial results for the half-year ended December 31, 2015. We analyze the earnings along side the following peers of ThromboGenics NV – BioInvent International AB and UCB S.A. (BINV-SE and UCB-BE) that have also reported for this period. Highlights Summary numbers: Revenues of EUR 5.22 million, ... Read more (Read more...)